DiaMedica Therapeutics Inc. (DMAC) Operating cash flow 2017–2025
DiaMedica Therapeutics Inc. (DMAC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$29.1MFY2025 · since FY2017: -$3.9M → -$29.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$29.1M | -31.6% |
| FY2024 | -$22.1M | -17.9% |
| FY2023 | -$18.7M | -62.7% |
| FY2022 | -$11.5M | +6.0% |
| FY2021 | -$12.3M | -33.4% |
| FY2020 | -$9.2M | -0.9% |
| FY2019 | -$9.1M | -59.8% |
| FY2018 | -$5.7M | -46.1% |
| FY2017 | -$3.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DMAC financial trends
DMAC RevenueDMAC Net incomeDMAC Net marginDMAC Gross profitDMAC Gross marginDMAC Operating incomeDMAC Operating marginDMAC Free cash flowDMAC Capital expendituresDMAC Return on equityDMAC Stock buybacksDMAC Dividends paidDMAC Total assetsDMAC Total liabilitiesDMAC Shareholders’ equityDMAC overview →